ask why

Latest research

Every new paper in 280 characters, with how strong the evidence is and what readers question about it. Free to read.

Oncology · Lancet · 2026-09-06

In patients with high-risk, inoperable early-stage NSCLC, adding atezolizumab to SBRT did not improve overall survival vs SBRT alone (HR 1.04; 2-year OS 82% in both groups). The trial closed for futility. Grade ≥3 adverse events were 12% vs 3%.

RCTn = 417
Daly et al. Induction and consolidation atezolizumab with stereotactic body radiation therapy versus radiation alone in high-risk, early-stage non-small-cell lung cancer (SWOG/NRG S1914): a multicentre, open-label, superiority, phase 3, randomised controlled trial
Gastroenterology · Lancet Gastroenterol Hepatol · 2026-08-25

In 342 patients with untreated unresectable hepatocellular carcinoma, adding atezolizumab plus bevacizumab to on-demand TACE lengthened median TACE-PFS (11.3 vs 7.0 months; HR 0.71). Overall survival, immature at interim analysis, showed no difference (HR 0.96).

RCTn = 342
Kudo et al. On-demand transarterial chemoembolisation combined with atezolizumab and bevacizumab in patients with untreated hepatocellular carcinoma (TALENTACE): a multicentre, randomised, open-label, phase 3 trial
Oncology · Lancet · 2026-08-22

In 201 patients with HCC and macrovascular invasion stable or responding on atezolizumab-bevacizumab, resection lengthened median time to treatment failure vs maintenance (20·4 vs 11·8 months; HR 0·60); grade 3–4 treatment-related events 39% vs 21%, 2 treatment-related deaths.

RCTn = 201
Sun et al. Liver resection after atezolizumab and bevacizumab versus maintenance therapy for locally advanced hepatocellular carcinoma (TALENTOP): a multicentre, open-label, randomised, phase 3 trial
Oncology · Ann Oncol · 2026-08-21

After chemoradiotherapy for unresectable oesophageal SCC, atezolizumab plus tiragolumab did not improve PFS (HR 0.82) or OS (HR 0.91) vs placebo, missing the primary endpoint. Atezolizumab alone had longer OS (HR 0.69; descriptive P). Treatment-related AEs: 74.8%, 65.2%, 55.4%.

RCTn = 760
Xu et al. Atezolizumab with or without tiragolumab in unresectable esophageal squamous-cell carcinoma following definitive concurrent chemoradiotherapy (SKYSCRAPER-07): a randomised, phase III study

Sign in to react

Enter your email and we send a one-time link. No password.

Your name and role

These appear beside any methods concern you post and on your profile page.